Granulocyte–macrophage colony‐stimulating factor (GM‐CSF) as a therapeutic target in psoriasis: randomized, controlled investigation using namilumab, a specific human anti‐GM‐CSF monoclonal antibody†

The relevance of granulocyte–macrophage colony‐stimulating factor (GM‐CSF) in the management of psoriasis has not been studied previously. GM‐CSF is important in the initiation and maintenance of chronic inflammatory processes.

• Publication year

  2018

• Venue

  British Journal of Dermatology

• Publication date

  2018-11-02

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/bjd.17195PMID 30207587PMCID 7379964
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• GM-CSF in inflammation

  2019cited by this paper
• Granulocyte–macrophage colony-stimulating factor inactivation in CAR T-cells prevents monocyte-dependent release of key cytokine release syndrome mediators

  2019cited by this paper
• Emerging therapies in rheumatoid arthritis: focus on monoclonal antibodies

  2019cited by this paper
• Phase 1b randomized, double-blind study of namilumab, an anti-granulocyte macrophage colony-stimulating factor monoclonal antibody, in mild-to-moderate rheumatoid arthritis

  2017cited by this paper
• Targeting GM-CSF in inflammatory diseases

  2016cited by this paper
• The global burden of psoriatic skin disease

  2015cited by this paper
• Synovial CD4+ T-cell-derived GM-CSF supports the differentiation of an inflammatory dendritic cell population in rheumatoid arthritis

  2015cited by this paper
• A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis.

  2015cited by this paper
• Tildrakizumab (MK‐3222), an anti‐interleukin‐23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo‐controlled trial

  2015cited by this paper
• Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials.

  2015cited by this paper
• New and emerging biologic therapies for moderate-to-severe plaque psoriasis: mechanistic rationales and recent clinical data for IL-17 and IL-23 inhibitors

  2015cited by this paper
• Secukinumab in plaque psoriasis--results of two phase 3 trials.

  2014cited by this paper
• Immunologic Biomarkers for Clinical and Therapeutic Management of Psoriasis

  2014cited by this paper
• IL-17 and GM-CSF Expression Are Antagonistically Regulated by Human T Helper Cells

  2014cited by this paper
• IL-17 targeted therapies for psoriasis

  2013cited by this paper
• The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses.

  2013cited by this paper
• Antibody biodistribution coefficients

  2013cited by this paper
• Placebo response in relation to clinical trial design: a systematic review and meta-analysis of randomized controlled trials for determining biologic efficacy in psoriasis treatment

  2012cited by this paper
• Targeting the Th17 pathway in psoriasis

  2012cited by this paper
• Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis.

  2012cited by this paper
• Mast Cells and Neutrophils Release IL-17 through Extracellular Trap Formation in Psoriasis

  2011cited by this paper
• Characteristics of a large cohort of patients with autoimmune pulmonary alveolar proteinosis in Japan.

  2008cited by this paper
• The MRC breathlessness scale.

  2008cited by this paper
• Pathogenesis and clinical features of psoriasis.

  2007cited by this paper
• Granulocyte-macrophage colony-stimulating factor (GM-CSF) and T-cell responses: what we do and don't know

  2006cited by this paper
• Serum Levels of TNF-α, IFN-γ, IL-6, IL-8, IL-12, IL-17, and IL-18 in Patients With Active Psoriasis and Correlation With Disease Severity

  2005cited by this paper
• Cytokine production by skin-derived mast cells: endogenous proteases are responsible for degradation of cytokines.

  2005cited by this paper
• Cytokine Production by Skin-Derived Mast Cells: Endogenous Proteases Are Responsible for Degradation of Cytokines 1

  2005cited by this paper
• Maculopapular eruption with enlarged macrophages in eight patients receiving G‐CSF or GM‐CSF

  2004cited by this paper
• In vivo activation of JAK2/STAT‐3 pathway during angiogenesis induced by GM‐CSF

  2002cited by this paper
• Endogenous Granulocyte-Macrophage Colony-Stimulating Factor Overexpression In Vivo Results in the Long-Term Recruitment of a Distinct Dendritic Cell Population with Enhanced Immunostimulatory Function1

  2002cited by this paper
• Effects of treatment with a fully human anti-tumour necrosis factor α monoclonal antibody on the local and systemic homeostasis of interleukin 1 and TNFα in patients with rheumatoid arthritis

  2001cited by this paper
• Cell-fate conversion of lymphoid-committed progenitors by instructive actions of cytokines

  2000cited by this paper
• Pharmacokinetic, pharmacodynamic and clinical effects of a humanized IgG1 anti-CD4 monoclonal antibody in the peripheral blood and synovial fluid of rheumatoid arthritis patients.

  2000cited by this paper
• Critical role of neutrophils for the generation of psoriasiform skin lesions in flaky skin mice.

  2000cited by this paper
• Correlated increases of tumour necrosis factor‐α, interleukin‐6 and granulocyte monocyte‐colony stimulating factor levels in suction blister fluids and sera of psoriatic patients relationships with disease severity

  1994cited by this paper
• GM-CSF activates regenerative epidermal growth and stimulates keratinocyte proliferation in human skin in vivo.

  1994cited by this paper
• Exacerbation of psoriasis with GM‐CSF therapy

  1993cited by this paper
• High amounts of circulating interleukin (IL)‐6 in the form of monomeric immune complexes during anti‐IL‐6 therapy. Towards a new methodology for measuring overall cytokine production in human in vivo

  1992cited by this paper
• Granulocyte-macrophage colony-stimulating factor in psoriasis.

  1990cited by this paper
• Keratinocyte derived T-cell growth factor (KTGF) is identical to granulocyte macrophage colony stimulating factor (GM-CSF).

  1988cited by this paper
• Keratinocyte growth regulation by the products of immune cells

  1988cited by this paper
• Severe psoriasis--oral therapy with a new retinoid.

  1978cited by this paper

• Tissue macrophages: origin, heterogenity, biological functions, diseases and therapeutic targets

  2025cites this paper
• Design of RESOLVE Lung, a multinational Phase 2, randomized, placebo-controlled trial of the anti-GM-CSF monoclonal antibody namilumab in patients with chronic pulmonary sarcoidosis.

  2025cites this paper
• GM-CSF+ Th: a central player in autoimmunity

  2025cites this paper
• Advancing insights into psoriasis: from pathogenesis to current and emerging therapies.

  2025cites this paper
• Mechanobiology of neutrophil inflammasome signaling in psoriasis.

  2025cites this paper
• Anti-GM-CSF autoantibodies in myeloid leukemias.

  2025cites this paper
• Cytokines in psoriasis: From pathogenesis to targeted therapy.

  2024cites this paper
• Expansion of granulocyte-macrophage colony-stimulating factor producing CD4+ T cells in an animal model with enhanced interleukin-1 signal

  2024cites this paper
• GMCSF: More an Inflammatory Immune ‘Cytokine’ Than a Growth Factor

  2024cites this paper
• Developmental drugs for sarcoidosis.

  2024cites this paper
• The Role of Neutrophils in Spondyloarthritis: A Journey across the Spectrum of Disease Manifestations

  2023cites this paper
• Transcriptomic Analysis of Hidradenitis Suppurativa: A Unique Molecular Signature with Broad Immune Activation

  2023cites this paper
• Gene Ontology Analysis Highlights Biological Processes Influencing Responsiveness to Biological Therapy in Psoriasis

  2023cites this paper
• Investigational systemic drugs for moderate to severe plaque psoriasis: What’s new?

  2023cites this paper
• Proinflammatory cytokines and their receptors as druggable targets to alleviate pathological pain.

  2022cites this paper
• Novel therapies in axial spondyloarthritis.

  2022cites this paper
• Recent advances in the prevention and management of cytokine release syndrome after chimeric antigen receptor T-cell therapy

  2022cites this paper
• Sarcoidosis: Updates on therapeutic drug trials and novel treatment approaches

  2022cites this paper
• Targeting GM-CSF in inflammatory and autoimmune disorders.

  2021cites this paper
• Efficacy of Systemic Treatments of Nail Psoriasis: A Systemic Literature Review and Meta-Analysis

  2021cites this paper
• CATALYST trial protocol: a multicentre, open-label, phase II, multiarm trial for an early and accelerated evaluation of the potential treatments for COVID-19 in hospitalised adults

  2021cites this paper
• GM-CSF: Master regulator of the T cell-phagocyte interface during inflammation.

  2021cites this paper
• The Role of GM-CSF Autoantibodies in Infection and Autoimmune Pulmonary Alveolar Proteinosis: A Concise Review

  2021cites this paper
• 30 Years of Biotherapeutics Development-What Have We Learned?

  2020cites this paper
• Emerging systemic drugs in the treatment of plaque psoriasis

  2020cites this paper
• GM-CSF: A Promising Target in Inflammation and Autoimmunity

  2020cites this paper
• Cytokine‐regulated Th17 plasticity in human health and diseases

  2020cites this paper
• Phage Display Derived Monoclonal Antibodies: From Bench to Bedside

  2020cites this paper
• Research Pipeline II: Upcoming Biologic Therapies

  2020cites this paper
• Precision medicine in psoriatic arthritis: how should we select targeted therapies?

  2019cites this paper
• Granulocyte–macrophage colony-stimulating factor inactivation in CAR T-cells prevents monocyte-dependent release of key cytokine release syndrome mediators

  2019cites this paper
• Research

  2019cites this paper
• King’s Research

  2019cites this paper
• Quoi de neuf en thérapeutique dermatologique ?

  2019cites this paper
• GM-CSF in inflammation

  2019cites this paper
• Emerging therapies in rheumatoid arthritis: focus on monoclonal antibodies

  2019cites this paper
• Targeting granulocyte‐monocyte colony‐stimulating factor in psoriasis. What a negative study can teach us

  2019cites this paper
• Biologics for psoriasis: What is new?

  2019cites this paper
• State of the art and pharmacological pipeline of biologics for chronic plaque psoriasis.

  2019cites this paper
• Regulatory T Cells Restrai n Pathogenic T Helper Cells during Skin Inflammation Graphical

  2018cites this paper
• Regulatory T Cells Restrain Pathogenic T Helper Cells during Skin Inflammation.

  2018cites this paper